BioNTech SE
BNTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BNTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BNTX
BioNTech SE is a German biotechnology company focused on developing immunotherapies for cancer and infectious diseases, with a core pipeline of oncology assets including BNT327 and antibody-drug conjugates, and a financial position supported by $7.7 billion in cash as of year-end 2025.
Key risk: Oncology pipeline failure risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2025.
Tracking 78 clinical trials · 8 catalysts for BioNTech SE.
BioNTech SE is a German biotechnology company focused on developing immunotherapies for cancer and infectious diseases, with a core pipeline of oncology assets including BNT327 and antibody-drug conjugates, and a financial position supported by $7.7 billion in cash as of year-end 2025.
- Cash and equivalents of $7,675.4M as of 2025-12-31 [sec].
- Total revenue of $2,869.9M for the year ended 2025-12-31 [sec].
- Net loss of $1,136.1M for the year ended 2025-12-31 [sec].
- Shareholders' equity of $20,055.6M as of 2025-12-31 [sec].
- Total debt of $622.1M as of 2025-12-31 [sec].
What works
- Strong cash position of $7.7B provides runway to fund extensive oncology pipeline and operations without near-term financing pressure [sec].
- Diverse oncology pipeline with multiple Phase 3 programs (e.g., BNT327, DB-1303, BNT113) targeting large markets [sec].
- Proprietary technology platforms (mRNA, ADC) enable potential differentiation in competitive oncology landscape [sec].
- Significant shareholder and management ownership concentration may align long-term interests with shareholders [sec].
What to weigh
- Net loss of $1.1B in 2025 reflects heavy R&D spending and declining COVID-19 vaccine revenue [sec].
- Clinical development is lengthy, expensive, and uncertain; delays or failures in oncology trials could materially harm the business [sec].
- Intense competition from larger pharmaceutical and biotech companies with greater resources may limit market penetration [sec].
- Dependence on successful development and regulatory approval of oncology candidates; failure would severely impact prospects [sec].
From the filings
Quoted directly from source documents.
Business depends on successful development of oncology assets like BNT327 and ADC candidates.
“Our business is dependent on the successful development, regulatory approval and commercialization of new medicinal product candidates based on our technology platforms, particularly our oncology assets including BNT327 and our antibody-drug conjugate, or ADC, clinical assets.”
SEC filings · March 10, 2026
Clinical development is lengthy, expensive, and uncertain.
“Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control.”
SEC filings · March 10, 2026
Competitors have significantly greater resources.
“Most of our competitors have significantly greater resources than we do and we may not be able to compete successfully.”
SEC filings · March 10, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline — Phase 2 Readout: oncology — Topline data from a Phase 2 oncology trial will provide early efficacy and safety signals.
- 2028-07-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemot — Phase 3 topline results for DB-1303 (ADC) compared to standard chemotherapy.
- 2029-03-01 · Phase3_Topline · bnt327 — Phase 3 Topline: A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy ( — Phase 3 topline data for BNT327 combined with chemotherapy in a double-blind setting.
- 2029-04-01 · Phase3_Topline · bnt113 — Phase 3 Topline: An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembr — Phase 3 topline results for BNT113 plus pembrolizumab versus pembrolizumab alone.
- 2029-11-01 · Phase3_Topline · bnt323 — Phase 3 Topline: A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice — Additional Phase 3 topline data for BNT323/DB-1303 versus investigator's choice chemotherapy.
- 2030-09-01 · Phase3_Topline · bnt327 — Phase 3 Topline: A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Ve — Second Phase 3 topline readout for BNT327 in combination with chemotherapy.
- 2031-02-01 · Phase3_Topline · bnt324 — Phase 3 Topline: A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in — Phase 3 topline data for BNT324 compared to docetaxel plus prednisone/prednisolone.
- 2031-12-01 · Phase3_Topline · bnt327 — Phase 3 Topline: A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination Wi — Phase 2/3 topline data from a master protocol trial of BNT327 in combination regimens.
Risks & what to watch (4)›
Key risks
- Oncology pipeline failure risk — If BNT327 or ADC candidates fail to gain approval, business would be materially harmed [sec].
- Clinical trial delays
- Intense competition — Larger competitors with more resources may outcompete in development and commercialization [sec].
- Funding needs uncertainty — Future capital requirements are uncertain; inability to raise funds could force pipeline cuts [sec].
What to watch
- Phase 2 topline readout for oncology candidate expected by 2026-12-31 [catalyst].
- Phase 3 topline data for DB-1303 (BNT323) expected by 2028-07-01 [catalyst].
- Phase 3 topline data for BNT327 in combination with chemotherapy expected by 2029-03-01 [catalyst].
- Phase 3 topline data for BNT113 in combination with pembrolizumab expected by 2029-04-01 [catalyst].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run BioNTech SE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioNTech SE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.14
No tracked pipeline phase
No tracked pipeline candidates
8 upcoming, next in ~123d
0 buys · 1 sell (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
271
Total value held
$3.68B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 5,709,240 | $507.4M |
| primecap management co/ca/ | 3,793,711 | $337.2M |
| flossbach von storch se | 3,680,315 | $327.1M |
| dodge & cox | 3,676,791 | $326.8M |
| bnp paribas financial markets | 1,651,959 | $148.3M |
| blackrock, inc. | 1,658,153 | $147.4M |
| citadel advisors llc | 1,540,682 | $136.9M |
| bank of america corp /de/ | 903,029 | $80.3M |
| gsk plc | 889,824 | $79.1M |
| baillie gifford & co | 882,572 | $78.4M |
Showing top 10 of 271 institutional holders of BioNTech SE. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.2%
- Days to cover
- 2.6
- Shares short
- 2,215,111
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BNTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for BioNTech SE?
BioNTech SE is a German biotechnology company focused on developing immunotherapies for cancer and infectious diseases, with a core pipeline of oncology assets including BNT327 and antibody-drug conjugates, and a financial position supported by $7.7 billion in cash as of year-end 2025.
What is BioNTech SE's next catalyst?
BioNTech SE's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: oncology" — expected December 31, 2026.
Who is the CEO of BioNTech SE?
Dr. Ugur Sahin M.D. is the chief executive officer of BioNTech SE (BNTX).
Where is BioNTech SE headquartered?
BioNTech SE (BNTX) is headquartered in Mainz, Germany.
What therapeutic areas does BioNTech SE focus on?
BioNTech SE develops therapies across Oncology, Gene Therapy, Immunology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.